Trial Profile
An Open-Label Multicenter Study Assessing the Long-Term Safety of a Once-Weekly and Once-Monthly, Long-Acting Subcutaneous Injection Depot of Buprenorphine (CAM2038) in Adult Outpatients with Opioid Use Disorder
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 May 2020
Price :
$35
*
At a glance
- Drugs Buprenorphine (Primary)
- Indications Opioid-related disorders
- Focus Adverse reactions; Registrational
- Sponsors Braeburn Pharmaceuticals
- 04 Jun 2019 Results presented in a Camurus Media Release.
- 04 Jun 2019 According to a Braeburn Pharmaceuticals media release, data from this trial were published in leading substance use disorder journal, Addiction.
- 04 Jun 2019 Results presented in the Braeburn Pharmaceuticals media release.